Immunotherapy plus chemo shows promise against rare lung cancer

NCT ID NCT06155279

Ongoing Disease control Sponsor: Istituto Oncologico Veneto IRCCS Source: ClinicalTrials.gov ↗

First seen Jan 22, 2026 · Last updated May 23, 2026 · Updated 20 times

Summary

This study tests whether giving the immunotherapy drug pembrolizumab along with standard chemotherapy before surgery can improve outcomes for people with a rare cancer called pleural mesothelioma. About 41 adults with early-stage, treatable mesothelioma will receive the drug combination, then surgery, followed by more pembrolizumab. The main goal is to see if this approach can eliminate all cancer cells in the removed tissue.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PLEURAL MESOTHELIOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo

Alessandria, Italy
Azienda Ospedaliera-Universitaria di Parma

Parma, Italy
Azienda Ospedaliero-Universitaria S. Anna

Ferrara, Italy
Centro di Riferimento Oncologico (CRO) IRCCS

Aviano, Pordenone, Italy
Humanitas Gavazzeni

Bergamo, Italia/Bergamo, 24125, Italy
IFO - Istituto Tumori Regina Elena, Roma

Roma, Italia/Roma, 00144, Italy
Istituto Clinico Humanitas

Rozzano, Milano, 20089, Italy
Istituto Oncologico Veneto IRCCS

Padova, 35128, Italy

Conditions

Explore the condition pages connected to this study.

PLEURAL MESOTHELIOMA